GlassScriptPhysician profile
Kulbir Sandhu
NPI 1629059043
$7,707.45
in general payments reported to CMS, 2019-2025
54 companies · $99.12 in 2025
The $99.12 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $872 · 2021: $1,042 · 2022: $1,789 · 2023: $1,669 · 2024: $648 · 2025: $99.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,107.77 | 2019-2024 | Jardiance, Mounjaro, Lyumjev |
| Novo Nordisk INC | $982.61 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $617.84 | 2019-2024 | Farxiga |
| Abbott Laboratories | $472.88 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $464.39 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $402.89 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.57 | 2019-2025 | Jardiance |
| Dexcom, INC. | $220.20 | 2019-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $219.50 | 2019-2024 | Synthroid, Ubrelvy |
| Antares Pharma, INC. | $201.51 | 2019-2024 | Xyosted |
| Ibsa Pharma INC. | $185.23 | 2019-2024 | Tirosint, Licart, Tirosint |
| Lifescan, INC. | $161.55 | 2019-2023 | |
| Pfizer INC. | $155.54 | 2019-2025 | |
| Insulet Corporation | $151.72 | 2019-2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $145.15 | 2020-2023 | Gvoke Hypopen |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kulbir Sandhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.